Latigo Biotherapeutics appointed Todd Smith as President and Chief Executive Officer, replacing Nima Farzan who resigned from the Board. The company reported a net loss of $20.9 million for the quarter ended September 30, 2026, with cash reserves of $401.2 million expected to fund operations into 2029. Latigo is a clinical-stage biopharmaceutical company developing non-opioid pain medicines.
